Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 3
2017 1
2018 2
2022 6
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study).
Siripongboonsitti T, Ungtrakul T, Tawinprai K, Nimmol T, Buttakosa M, Sornsamdang G, Jarrusrojwuttikul T, Silapant P, Mahanonda N. Siripongboonsitti T, et al. Among authors: sornsamdang g. Int J Infect Dis. 2023 Sep;134:211-219. doi: 10.1016/j.ijid.2023.06.018. Epub 2023 Jun 30. Int J Infect Dis. 2023. PMID: 37393041 Free article. Clinical Trial.
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
Cohen G, Jungsomsri P, Sangwongwanich J, Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Cohen G, et al. Among authors: sornsamdang g. Hum Vaccin Immunother. 2022 Nov 30;18(5):2052525. doi: 10.1080/21645515.2022.2052525. Epub 2022 Mar 24. Hum Vaccin Immunother. 2022. PMID: 35323079 Free PMC article.
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.
Tawinprai K, Jungsomsri P, Pinijnai O, Tavonvunchai F, Lievjaroen A, Suwannaroj P, Siripongboonsitti T, Porntharukchareon T, Sornsamdang G, Ungtrakul T. Tawinprai K, et al. Among authors: sornsamdang g. Hum Vaccin Immunother. 2023 Dec 31;19(1):2206360. doi: 10.1080/21645515.2023.2206360. Epub 2023 May 4. Hum Vaccin Immunother. 2023. PMID: 37140889 Free PMC article.
Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Tawinprai K, et al. Among authors: sornsamdang g. Expert Rev Vaccines. 2022 Dec;21(12):1873-1881. doi: 10.1080/14760584.2022.2099380. Epub 2022 Jul 13. Expert Rev Vaccines. 2022. PMID: 35792752 Clinical Trial.
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Dechates B, Monprach H, Sornsamdang G, Wittayasak K, Soonklang K, Mahanonda N. Tawinprai K, et al. Among authors: sornsamdang g. Hum Vaccin Immunother. 2022 Dec 31;18(1):2035573. doi: 10.1080/21645515.2022.2035573. Epub 2022 Mar 3. Hum Vaccin Immunother. 2022. PMID: 35240945 Free PMC article.
Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Tawinprai K, et al. Among authors: sornsamdang g. Vaccine. 2022 Mar 15;40(12):1761-1767. doi: 10.1016/j.vaccine.2022.02.019. Epub 2022 Feb 21. Vaccine. 2022. PMID: 35210118 Free PMC article. Clinical Trial.
Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population.
Sirisreetreerux S, Porntharukchareon T, Dechates B, Rangsrisaeneepitak V, Therawit P, Worawitchawong S, Sornsamdang G, Soonklang K, Tawinprai K. Sirisreetreerux S, et al. Among authors: sornsamdang g. Sci Rep. 2023 Jul 21;13(1):11798. doi: 10.1038/s41598-023-39114-5. Sci Rep. 2023. PMID: 37479776 Free PMC article.
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Vanichsetakul P, Thonginnetra S, Niemsorn K, Promsena P, Tandhansakul M, Kasemlawan N, Ruangkijpaisal N, Banomyong N, Phattraprayoon N, Ungtrakul T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Mahanonda N. Tawinprai K, et al. Among authors: sornsamdang g. Vaccines (Basel). 2022 May 19;10(5):807. doi: 10.3390/vaccines10050807. Vaccines (Basel). 2022. PMID: 35632562 Free PMC article.
SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand.
Ungtrakul T, Sornsamdang G, Soonklang K, Saeloo S, Wittayasak K, Suptawiwat O, Pulmanausahakul R, Phattraprayoon N, Auewarakul C, Mahanonda N. Ungtrakul T, et al. Among authors: sornsamdang g. Public Health Pract (Oxf). 2022 Dec;4:100341. doi: 10.1016/j.puhip.2022.100341. Epub 2022 Nov 6. Public Health Pract (Oxf). 2022. PMID: 36373034 Free PMC article.
19 results